Frontlight ResearchEarly access
CompletedNo phase
China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population
Key facts
- Who runs it
- Edwards Lifesciences
- Where
- China4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 58 people enrolled
- Started
- 23 May 2018
- Ended
- 19 Jun 2024
- Type of study
- Interventional
- Treatments tested
- SAPIEN 3 THV with the Commander delivery system
- Record updated
- 10 September 2025
Who can take part
- Age
- 60 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Subjects who are considered to be operable and high risk for surgical valve replacement: STS Score ≥ 8 and ≤ 15 or Logistic EuroSCORE ≥ 15 and ≤ 40. If STS score is below 8 and Logistic EuroSCORE is below 15, patients should have other clinical or anatomical risk factors that would be considered high risk for surgery and documented by the heart team
- Severe symptomatic aortic stenosis requiring aortic valve replacement characterized by one or more of the following within 60 days prior to the index procedure: AVA < 0.8 cm2, Indexed AVA <0.5 cm2/m2, mean gradient > 40mmHg, or peak aortic jet velocity > 4.0m/sec
- NYHA Functional Class II or greater
- The study patient or the study patient's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the EC of the respective clinical site
- The study patient agrees to comply with all required postprocedure follow-up visits
Who cannot take part
- Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment
- Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation >3+)
- Aortic valve is bicuspid and the patient is less than 60 years old, or the aortic valve is bicuspid with no raphe (Sievers classification type 0)
- Aortic valve is a congenital unicuspid or is non-calcified
- Anomalous coronary artery that would interfere with proper placement of the valve
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve implantation (TAVI) in Chinese patients with symptomatic severe calcific aortic stenosis who are considered at high risk for surgical valve replacement.
The group in the trial
- Patients with SAPIEN 3 THVTreatment being tested
Patients will be treated with Edwards SAPIEN 3 Transcatheter Heart Valve and Commander delivery system
Treatment: SAPIEN 3 THV with the Commander delivery system
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 Transcatheter Heart Valve (THV) in the Chinese Population
- Record updated
- 10 September 2025